Sepsis in cancer patients represents a rapidly growing global challenge driven by rising cancer burden, improved survival, and increasing use of immunosuppressive therapies. These oncologic patients experience unique vulnerabilities including immune dysregulation, treatment-related cytopenias, and anatomical disruptions that increase susceptibility to severe infections and complicate early recognition. This manuscript navigates the full sepsis continuum in cancer patients, from epidemiology and diagnostic challenges, including low blood-culture yield, atypical clinical presentations, and delays in identifying the source of infections, to the need for biomarker-guided strategies, rapid molecular diagnostics, and metagenomic testing, and a review of emerging future directions. Despite the advances, mortality remains high across cancer types, though recent data demonstrate modest improvements with earlier ICU admission, timely antimicrobials, and individualized organ-support strategies. Precision antimicrobial therapy, PK/PD-guided dosing, and stewardship practices are essential to optimize treatment while minimizing toxicities and resistance. Emerging tools, AI-driven prediction models, microbiome-preserving interventions, and personalized risk-profiling offer promising avenues to enhance early detection, prognostication, and tailored therapy. Future work requires inclusive trials and integrated oncologic-critical care frameworks to improve outcomes.